Tags

Type your tag names separated by a space and hit enter

Potential Role of Gut Microbiota in Traditional Chinese Medicine against COVID-19.
Am J Chin Med. 2021; 49(4):785-803.AJ

Abstract

The coronavirus disease 2019 (COVID-19) spreads and rages around the world and threatens human life. It is disappointing that there are no specific drugs until now. The combination of traditional Chinese medicine (TCM) and western medication seems to be the current more effective treatment strategy for COVID-19 patients in China. In this review, we mainly discussed the relationship between COVID-19 and gut microbiota (GM), as well as the possible impact of TCM combined with western medication on GM in the treatment of COVID-19 patients, aiming to provide references for the possible role of GM in TCM against COVID-19. The available data suggest that GM dysbiosis did occur in COVID-19 patients, and the intervention of GM could ameliorate the clinical condition of COVID-19 patients. In addition, TCMs (e.g., Jinhua Qinggan granule, Lianhua Qingwen capsule, Qingfei Paidu decoction, Shufeng Jiedu capsule, Qingjin Jianghuo decoction, Toujie Quwen granules, and MaxingShigan) have been proven to be safe and effective for the treatment of COVID-19 in Chinese clinic. Among them, Ephedra sinica, Glycyrrhiza uralensis, Bupleurum chinense, Lonicera japonica,Scutellaria baicalensi, and Astragalus membranaceus are common herbs and have a certain regulation on GM, immunity, and angiotensin converting enzyme 2 (ACE2). Notably, Qingfei Paidu decoction and MaxingShigan have been demonstrated to modulate GM. Finally, the hypothesis of GM-mediated TCM treatment of COVID-19 is proposed, and more clinical trials and basic experiments need to be initiated to confirm this hypothesis.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Zhang Q
Key Laboratory of Shaanxi Administration of Traditional Chinese, Medicine for TCM Compatibility, State Key Laboratory of Research and Development of Characteristic, Qin Medicine Resources (Cultivation), Shaanxi Collaborative Innovation Center of Chinese Medicinal, Resources Industrialization, Shaanxi University of Chinese Medicine, Xi'an, 712046, P. R. China.
Yue S
Key Laboratory of Shaanxi Administration of Traditional Chinese, Medicine for TCM Compatibility, State Key Laboratory of Research and Development of Characteristic, Qin Medicine Resources (Cultivation), Shaanxi Collaborative Innovation Center of Chinese Medicinal, Resources Industrialization, Shaanxi University of Chinese Medicine, Xi'an, 712046, P. R. China.
Wang W
Key Laboratory of Shaanxi Administration of Traditional Chinese, Medicine for TCM Compatibility, State Key Laboratory of Research and Development of Characteristic, Qin Medicine Resources (Cultivation), Shaanxi Collaborative Innovation Center of Chinese Medicinal, Resources Industrialization, Shaanxi University of Chinese Medicine, Xi'an, 712046, P. R. China.
Chen Y
Key Laboratory of Shaanxi Administration of Traditional Chinese, Medicine for TCM Compatibility, State Key Laboratory of Research and Development of Characteristic, Qin Medicine Resources (Cultivation), Shaanxi Collaborative Innovation Center of Chinese Medicinal, Resources Industrialization, Shaanxi University of Chinese Medicine, Xi'an, 712046, P. R. China.
Zhao C
Key Laboratory of Shaanxi Administration of Traditional Chinese, Medicine for TCM Compatibility, State Key Laboratory of Research and Development of Characteristic, Qin Medicine Resources (Cultivation), Shaanxi Collaborative Innovation Center of Chinese Medicinal, Resources Industrialization, Shaanxi University of Chinese Medicine, Xi'an, 712046, P. R. China.
Song Y
Key Laboratory of Shaanxi Administration of Traditional Chinese, Medicine for TCM Compatibility, State Key Laboratory of Research and Development of Characteristic, Qin Medicine Resources (Cultivation), Shaanxi Collaborative Innovation Center of Chinese Medicinal, Resources Industrialization, Shaanxi University of Chinese Medicine, Xi'an, 712046, P. R. China.
Yan D
Beijing Friendship Hospital, Capital Medical University, Beijing 100050, P. R. China.
Zhang L
Hanlin College, Nanjing University of Chinese Medicine, Taizhou 225300, Jiangsu Province, P. R. China.
Tang Y
Key Laboratory of Shaanxi Administration of Traditional Chinese, Medicine for TCM Compatibility, State Key Laboratory of Research and Development of Characteristic, Qin Medicine Resources (Cultivation), Shaanxi Collaborative Innovation Center of Chinese Medicinal, Resources Industrialization, Shaanxi University of Chinese Medicine, Xi'an, 712046, P. R. China.

MeSH

COVID-19Gastrointestinal MicrobiomeMedicine, Chinese TraditionalPandemicsSARS-CoV-2

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

33853498

Citation

Zhang, Qiao, et al. "Potential Role of Gut Microbiota in Traditional Chinese Medicine Against COVID-19." The American Journal of Chinese Medicine, vol. 49, no. 4, 2021, pp. 785-803.
Zhang Q, Yue S, Wang W, et al. Potential Role of Gut Microbiota in Traditional Chinese Medicine against COVID-19. Am J Chin Med. 2021;49(4):785-803.
Zhang, Q., Yue, S., Wang, W., Chen, Y., Zhao, C., Song, Y., Yan, D., Zhang, L., & Tang, Y. (2021). Potential Role of Gut Microbiota in Traditional Chinese Medicine against COVID-19. The American Journal of Chinese Medicine, 49(4), 785-803. https://doi.org/10.1142/S0192415X21500373
Zhang Q, et al. Potential Role of Gut Microbiota in Traditional Chinese Medicine Against COVID-19. Am J Chin Med. 2021;49(4):785-803. PubMed PMID: 33853498.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Potential Role of Gut Microbiota in Traditional Chinese Medicine against COVID-19. AU - Zhang,Qiao, AU - Yue,Shijun, AU - Wang,Wenxiao, AU - Chen,Yanyan, AU - Zhao,Chongbo, AU - Song,Yijun, AU - Yan,Dan, AU - Zhang,Li, AU - Tang,Yuping, Y1 - 2021/04/09/ PY - 2021/4/16/pubmed PY - 2021/5/18/medline PY - 2021/4/15/entrez KW - ACE2 KW - COVID-19 KW - Gut Microbiota KW - Review KW - SARS-CoV-2 KW - Traditional Chinese Medicine SP - 785 EP - 803 JF - The American journal of Chinese medicine JO - Am J Chin Med VL - 49 IS - 4 N2 - The coronavirus disease 2019 (COVID-19) spreads and rages around the world and threatens human life. It is disappointing that there are no specific drugs until now. The combination of traditional Chinese medicine (TCM) and western medication seems to be the current more effective treatment strategy for COVID-19 patients in China. In this review, we mainly discussed the relationship between COVID-19 and gut microbiota (GM), as well as the possible impact of TCM combined with western medication on GM in the treatment of COVID-19 patients, aiming to provide references for the possible role of GM in TCM against COVID-19. The available data suggest that GM dysbiosis did occur in COVID-19 patients, and the intervention of GM could ameliorate the clinical condition of COVID-19 patients. In addition, TCMs (e.g., Jinhua Qinggan granule, Lianhua Qingwen capsule, Qingfei Paidu decoction, Shufeng Jiedu capsule, Qingjin Jianghuo decoction, Toujie Quwen granules, and MaxingShigan) have been proven to be safe and effective for the treatment of COVID-19 in Chinese clinic. Among them, Ephedra sinica, Glycyrrhiza uralensis, Bupleurum chinense, Lonicera japonica,Scutellaria baicalensi, and Astragalus membranaceus are common herbs and have a certain regulation on GM, immunity, and angiotensin converting enzyme 2 (ACE2). Notably, Qingfei Paidu decoction and MaxingShigan have been demonstrated to modulate GM. Finally, the hypothesis of GM-mediated TCM treatment of COVID-19 is proposed, and more clinical trials and basic experiments need to be initiated to confirm this hypothesis. SN - 1793-6853 UR - https://www.unboundmedicine.com/medline/citation/33853498/Potential_Role_of_Gut_Microbiota_in_Traditional_Chinese_Medicine_against_COVID_19_ DB - PRIME DP - Unbound Medicine ER -